Table 1.
Relationships of EGFL6 expression with clinical parameters in 150 patients with lung adenocarcinoma
| Cytoplasmic staining of EGFL6 | Total | P values | ||
| Low (0, 1+) | High (2+) | |||
| Gender | ||||
| Female | 24 (34.3) | 46 (65.7) | 70 | 0.817 |
| Male | 26 (32.5) | 54 (67.5) | 80 | |
| Grade | ||||
| Well | 8 (36.4) | 14 (63.6) | 22 | 0.744 |
| Moderate, poor | 42 (32.8) | 86 (67.2) | 128 | |
| Age | ||||
| ≤63 | 27 (35.5) | 49 (64.5) | 76 | 0.564 |
| >63 | 23 (31.1) | 51 (68.9) | 74 | |
| T status | ||||
| T1 | 19 (35.2) | 35 (64.8) | 54 | 0.718 |
| T2, T3, T4 | 31 (32.3) | 65 (67.7) | 96 | |
| Lymph node metastasis | ||||
| No | 26 (29.9) | 61 (70.1) | 87 | 0.292 |
| Yes | 24 (38.1) | 39 (61.9) | 63 | |
| Stage | ||||
| I | 19 (30.6) | 43 (69.4) | 62 | 0.558 |
| II, III, IV | 31 (35.2) | 57 (64.8) | 88 | |
EGFL6, epidermal growth factor-like domain 6.